Trial Profile

Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) for Depression

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sertraline (Primary) ; Bupropion
Indications Major depressive disorder
Focus Biomarker; Therapeutic Use
Acronyms EMBARC

Most Recent Events

28 Apr 2025 According to an Alto Neuroscience Inc media release, data from this trial was presented at the Society of Biological Psychiatry (SOBP) Annual Meeting, in Toronto, Canada, held April 24-26, 2025.
28 Apr 2025 Results presented in the Alto Neuroscience Inc media release.
15 Mar 2022 Key results published in the Biological Psychiatry

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com